Artificial Intelligence in Pharmaceutical Quality Assurance and Good Manufacturing Practice (GMP): Applications, Challenges and Future Perspectives

Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, offering significant potential to enhance the development, manufacturing, and quality assurance of active pharmaceutical ingredients (APIs) and medicinal products. By enabling advanced data analysis, predictive modeling, real-time monitoring, and automation, AI supports improved efficiency, reduced human error, accelerated time-to-market, and stronger regulatory compliance. Key AI techniques—including machine learning, deep learning, artificial neural networks, natural language processing, and computer vision—are increasingly applied across drug discovery, formulation, chemical synthesis, manufacturing, quality control, and regulatory documentation. In particular, AI-driven solutions strengthen pharmaceutical quality assurance and Good Manufacturing Practice (GMP) compliance by enabling automated defect detection, predictive quality control, anomaly identification, and process optimization. While AI adoption presents opportunities for enhanced performance and patient safety, it also necessitates responsible implementation in line with evolving regulatory frameworks such as EU-GMP Annex 11. In regions like Sub-Saharan Africa, and specifically Kenya, AI offers strategic potential to overcome structural and regulatory challenges, improve manufacturing standards, and align local production with global quality expectations. Also learn more about future opportunities, regulatory concerns and challenges of AI implementation. Overall, AI represents a central enabler of the fourth industrial revolution in pharma, driving data-driven insights, operational efficiency, and improved patient access to medicines.